United Online, Inc. Message Board

PBF is exploring MLP options. What are consequences for current shareholders?

1. Shareholder get MLP units - unlikely based on SD and CVI spinoffs. They sold units to raise capital.
2. Pay special dividend.
3. Expand operations with sale price.

Any thoughts?
LOL

Sentiment: Buy

Wed news came out that Carlyle Group has raised its stake in YRCW to 18.1%

This must be news causing big pop today.

What does it all mean? Active shareholder? Buyout interest?

It seems with large obligations, and low book, buyout is improbable. Perhaps they believe new CEO can indeed turn YRCW into a $40 stock.

LOL

Sentiment: Hold

Current Yahoo eps estimates for 2013, 2014 are 1.23 and 1.54 respectively. I assume numbers are based on pre-secondary issue or 20.5m shares.

If they sold about 11m shares, new outstanding is 32 mil. Thus dilutive affect is 20/32 or 62%. All estimates should be factored by .62. That is new 2013 eps est. is 0.48.

Does the above logic sound reasonable? Of course, over time, new money will be put to work and EBTIDA will rise.

LOL

Sentiment: Buy

Perhaps someone can explain Yahoo Finance (and others ) stat of EPS (ttm).
EDG EPS (ttm) is reported as -1.39.
However, last 4 Quarters adjusted are: 0.11, 0.24, 0.25, -0.07. It totals 0.54.
Why is there a discrepancy?

I think if investors saw a positve EPS, they would be more inclined to buy.
LOL

Sentiment: Buy

MRC seems to be the closest competitor to EDG. I use it as a leading indicator. So far, my value investing approach to EDG has produced losses.

Why has MRC performed so differently than EDG? MRC reports Q1 eps of 0.43 on 1.3 B revenue. EDG, which sells much the same product line, reported loss of 0.16. Revenue of $406m declined 20% from year ago.

Analysts are estimated positive earnings for remainder of year 0.83, and 1.24 in 2014. This seems a pretty good value proposition.

Is it the entire market (drilling rigs, etc.) that is weak? Is MRC taking market share from the weaker EDG?

Bottom line: Is EDG a Buy, Sell or Hold.

Sentiment: Buy

I think GTAT is following CREE's new business model. The model calls for not only making LED components, but making the actual lighting fixtures. Look at performance of CREE. Story was mentioned on Cramer's Mad Money.

GTAT expanded portfolio of Saphire related technologies allows an integrated approach. They can make both the raw material "boule" of saphire, and make the components - saphire screens. Moreover, as the "experts", they will expand saphire usage with new applications.

BTW - since the sun is still shining, solar is not going away. Increased solar efficiency will ultimately propel GTAT's solar division. This represents their largest potential.

LOL and see you at $10.

Sentiment: Buy

Mention about dilution by 10 million new shares from convertible preferred at 21.

1. What are convertible terms?
2. Is conversion forced?
3. Isn't convertible already included in diluted shares outstanding at 33 mil?
4. Will conversion help since price is above book; and eliminate interest expense?

LOL

Sentiment: Buy

CC said no change in reimbursement policy from health insurance providers.

On metrics alone, QCOR should be seling for PE of 15 and pps of 50.

The one big black swan overhang is insurance reimbursement. It is why QCOR continues to sell at low PE. As Street realizes that Achar is legitimate therapy and will continue to be paid for, QCOR will appreciate to intrinsic value - $50+++.

LOL

Sentiment: Strong Buy

ANW is looking at two important events:
1. Q1 earnings on May 13.
2. Credit agreement due end of April 2013.

Apparently, credit agreement has not be signed. But, ANW might announce at earnings CC.

Earnings should benefit from 1) sale of ships; 2) less bunkering days; 3) opening Barcelona.

I think imminent credit agreement, and it pass promised date is hurting ANW pps the most.

Sentiment: Buy

Based on revenue and eps metrics, QCOR should be selling at minimally 15 PE. But investors should carefully consider downside risk.

What are they for QCOR?
1. Insurance providers lower/remove coverage.
2. Competition from generic or alternative therapies.
3. Pricing deterioration due to competitio

n of government mandates.

Insurer risk seems to have diminished after AETNA scare. No additional insurers have added restrictions.

Competition is big unknown. QCOR is one trick pony with Acthar Gel. However, so far there is no hint of generic or alternates. Also, QCOR continues to add indications. The result is competion in one indication (MS), would not devastate company.

Pricing risk is real. Medicare/Medicaid can always reduce payments. But, Acthar is life saving, and the present administration seems quite friendly to the "Health at any cost" philosophy.

My humble opinion is that downside risk is minimal (-5) to one year upside (+20).

That's it for my Sunday review of the big picture.
LOL

Sentiment: Buy

Lufkin (LUFK) taken out by GE. Its oil field equip mfg and supplier. Implication is that this field has lots of upside.

How does major buyout affect EDG outlook? Very low trading volume. So far EDG has gone down based on 1H guidance.

LOL

Sentiment: Buy

Favus Institutional Research issued sell rating. Stock drops 3 pts over 2 days.

Does anyone know what were details in their report? What exactly are the arguments to sell at this price?

LOL

Sentiment: Buy

There are many eps estimates for ABX. What range of gold price is factored into these estimates?

LOL

Sentiment: Buy